ICER report for peanut OIT comes up short

Thomas Eiwegger; Katherine Anagnostou; Stefania Arasi; Philippe Bégin; Moshe Ben-Shoshan; Kirsten Beyer; Katharina Blumchen; Helen Brough; Jean Christoph Caubet; Edmond S. Chan; Sharon Chinthrajah; Carla M. Davis; Anne Des Roches; George Du Toit; Arnon Elizur; Stephen J. Galli; Geir Håland; Karin Hoffmann-Sommergruber; Harold Kim; Donald Y.M. Leung; Antonella Muraro; Ulugbek B. Nurmatov; Giovanni B. Pajno; Sayantani Sindher; Zsolt Szepfalusi; Maria Jose Torres; Julia Upton; Margitta Worm; Kari Nadeau

doi:10.1016/j.anai.2019.09.001

ICER report for peanut OIT comes up short

Thomas Eiwegger, Katherine Anagnostou, Stefania Arasi, Philippe Bégin, Moshe Ben-Shoshan, Kirsten Beyer, Katharina Blumchen, Helen Brough, Jean Christoph Caubet, Edmond S. Chan, Sharon Chinthrajah, Carla M. Davis, Anne Des Roches, George Du Toit, Arnon Elizur, Stephen J. Galli, Geir Håland, Karin Hoffmann-Sommergruber, Harold Kim, Donald Y.M. LeungAntonella Muraro, Ulugbek B. Nurmatov, Giovanni B. Pajno, Sayantani Sindher, Zsolt Szepfalusi, Maria Jose Torres, Julia Upton, Margitta Worm, Kari Nadeau

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Original language	English
Pages (from-to)	430-432
Number of pages	3
Journal	Annals of Allergy, Asthma and Immunology
Volume	123
Issue number	5
DOIs	https://doi.org/10.1016/j.anai.2019.09.001
State	Published - Nov 2019
Externally published	Yes

Access to Document

10.1016/j.anai.2019.09.001

Cite this

Eiwegger, T., Anagnostou, K., Arasi, S., Bégin, P., Ben-Shoshan, M., Beyer, K., Blumchen, K., Brough, H., Caubet, J. C., Chan, E. S., Chinthrajah, S., Davis, C. M., Roches, A. D., Du Toit, G., Elizur, A., Galli, S. J., Håland, G., Hoffmann-Sommergruber, K., Kim, H., ... Nadeau, K. (2019). ICER report for peanut OIT comes up short. Annals of Allergy, Asthma and Immunology, 123(5), 430-432. https://doi.org/10.1016/j.anai.2019.09.001

@article{014779f028074e82822d877b98e5b163,

title = "ICER report for peanut OIT comes up short",

author = "Thomas Eiwegger and Katherine Anagnostou and Stefania Arasi and Philippe B{\'e}gin and Moshe Ben-Shoshan and Kirsten Beyer and Katharina Blumchen and Helen Brough and Caubet, {Jean Christoph} and Chan, {Edmond S.} and Sharon Chinthrajah and Davis, {Carla M.} and Roches, {Anne Des} and {Du Toit}, George and Arnon Elizur and Galli, {Stephen J.} and Geir H{\aa}land and Karin Hoffmann-Sommergruber and Harold Kim and Leung, {Donald Y.M.} and Antonella Muraro and Nurmatov, {Ulugbek B.} and Pajno, {Giovanni B.} and Sayantani Sindher and Zsolt Szepfalusi and Torres, {Maria Jose} and Julia Upton and Margitta Worm and Kari Nadeau",

note = "Funding Information: Disclosures: Thomas Eiwegger received funding or has research contracts with DBV Technologies, ALK, Food Allergy and Anaphylaxis Program SickKids, Innovation Funds Denmark, and contributes to investigator-initiated OIT studies. Katherine Anagnostou has research contracts with Aimmune Therapeutics Inc and receives honoraria from ACAAI, and Colorado Allergy and Asthma Society (CAAS). Stefania Arasi has nothing to disclose. Philippe B{\'e}gin has received grants from Fonds de Recherche en Sant{\'e} du Qu{\'e}bec, Canadian Allergy, Asthma and Immunology Foundation, DBV Technologies, Sanofi Genzyme, Merck and Regeneron and personal fees from Aralez, Novartis and ALK outside the submitted work. Moshe Ben-Shoshan is a co-investigator for Aimmune and currently is involved in OIT studies. Kirsten Beyer reports outside the submitted work grants and personal fees from Aimmune, Danone, Infectopharm, personal fees from Bencard, Hycor, Mabylon AG, Mylan, Nestle, and grants from ALK, DBV Technologies, and Hipp. Katharina Blumchen has received personal fees and nonfinancial support from Novartis; personal fees from HAL Allergy, ThermoFisher, Bencard Allergie, Allergopharma, ALK, DBV, Nestle, Nutricia; grants and personal fees from Aimmune Therapeutics, and a grant from Hipp. Helen Brough serves on the UK Advisory Board for DBV Technologies and has received research support from ThermoScientific. Jean-Christoph Caubet has nothing to disclose. Edmond Chan has received research support from DBV Technologies, has been a member of advisory boards for Pfizer, Pediapharm, Leo Pharma, and Kaleo, is a member of the scientific advisory board for Food Allergy Canada, and was an expert panel and coordinating committee member of the National Institute of Allergy and Infectious Diseases (NIAID)-sponsored Guidelines for Peanut Allergy Prevention. Sharon Chinthrajah receives grant support from CoFAR NIAID, Aimmune, DBV Technologies, Astellas, AnaptysBio, Novartis, Regeneron, Stallergenes-Greer, and Boehringer Ingelheim, and is a scientific advisory board member for Alladapt Immunotherapeutics. Carla M. Davis is a co-investigator and contracts for Aimmune Therapeutics,Inc, DBV Technologies, Regeneron, Allakos, Inc, and the scientific advisory board for DBV technologies. Anne Des Roches has received grants from ALK and personal fees from Novartis and ALK outside the submitted work. George Du Toit is a scientific advisory board member of Aimmune, co-investigator on Aimmune-funded peanut Immunotherapy trials, UK Advisory Board for DBV Technologies, holds equity in DBV technologies, and is a lecturer at Allergy Symposia supported by Pharma companies, including Mylan and Aimmune. Arnon Elizur has nothing to disclose. Stephen J. Galli has received funding from NIH grants NIH/NIAID U19AI104209, NIH/NIAMS R01 AR067145, NIH/NIAID R01 AI125567, and NIH/NIAID R01 AI32494 and the United States-Israel Binational Foundation (Grant 2017182). Geir Haland has nothing to disclose. Karin Hoffmann-Sommergruber has received grants from Austrian Science Fund and Horizon 2020 (Cost action) and honoraria from Nutricia; and travel reimbursement from EAACI. Harold Kim served as speaker /or advisor for ALK, Aralez, Astrazeneca, CSL Behring, Shire, Novartis, Pediapharm, Stallergenes, Kaleo, Sanofi, Pfizer, and Mylan. Donald Y.M. Leung is Chairman of Aimmune Therapeutics, Inc DSMC; receives funding from NIH grants NIH/NIAMS R01 AR41256, NIH/NIAID U19 AI117673, NIH/NCRR UL1RR025780, NIH/NIAID UM1AI130780, and NIH/NIAID 1UM2AI130836, and consulted for Sanofi, Regeneron, Demira, and Novartis. Antonella Muraro has received a speaker's fee for DBV Technologies, Aimmune, serves as Chair of the EAACI Food Allergy and Anaphylaxis Guidelines. Ulugbek Nurmatov has nothing to disclose. Giovanni Battista Pajno has nothing to disclose. Sayantani Sindher conducted sponsored research for clinical trials from Aimmune, DBV Technologies, Sanofi, and Regeneron. Zsolt Szepfalusi has received honoraria from ThermoFisher, Milupa, Allergopharma, Shire, Bencard, Novartis, Meda, Vertex. Maria Jose Torres has been involved in collaboration with ALK-Abello. Julia Upton is a current or prior investigator for DBV Technologies, Aimmune, Regeneron, and investigator lead OIT studies (Food Allergy and Anaphylaxis Program SickKids), serves on the advisory board Kaleo, Food Allergy and Anaphylaxis Chair CSACI, and is a member of the scientific advisory board for Food Allergy Canada. Margitta Worm reports outside the submitted work grants and personal fees from Aimmune, Mylan, ALK, DBV Technologies, Allergopharma, Regenron, Sanofi, EliLilly, Stallergene, Bencard, HAL and Novartis. Kari Nadeau receives grant support from NIAID, Food Allergy Research & Education, End Allergies Together, Allergenis, Ukko; Personal Fees from Regeneron, AstraZeneca, ImmuneWorks, Cour; Sponsored research from Novartis, Sanofi, Astellas, Nestle; Sponsored research for clinical trials from Genentech, Aimmune Therapeutics, DBV Technologies, AnaptysBio, Stallergenes-Greer, Regeneron, and Adare Pharmaceuticals; Data and Safety Monitoring Board member at Novartis and NHLBI; Co-founded Before Brands, Alladapt Immunotherapeutics, and ForTra; Grant awardee for NIAID, NHLBI, NIEHS, and EPA; Director for Food Allergy Research & Education and WAO Center of Excellence. Funding Sources: None.",

year = "2019",

month = nov,

doi = "10.1016/j.anai.2019.09.001",

language = "English",

volume = "123",

pages = "430--432",

journal = "Annals of Allergy, Asthma and Immunology",

issn = "1081-1206",

publisher = "American College of Allergy, Asthma and Immunology",

number = "5",

}

Eiwegger, T, Anagnostou, K, Arasi, S, Bégin, P, Ben-Shoshan, M, Beyer, K, Blumchen, K, Brough, H, Caubet, JC, Chan, ES, Chinthrajah, S, Davis, CM, Roches, AD, Du Toit, G, Elizur, A, Galli, SJ, Håland, G, Hoffmann-Sommergruber, K, Kim, H, Leung, DYM, Muraro, A, Nurmatov, UB, Pajno, GB, Sindher, S, Szepfalusi, Z, Torres, MJ, Upton, J, Worm, M & Nadeau, K 2019, 'ICER report for peanut OIT comes up short', Annals of Allergy, Asthma and Immunology, vol. 123, no. 5, pp. 430-432. https://doi.org/10.1016/j.anai.2019.09.001

TY - JOUR

T1 - ICER report for peanut OIT comes up short

AU - Eiwegger, Thomas

AU - Anagnostou, Katherine

AU - Arasi, Stefania

AU - Bégin, Philippe

AU - Ben-Shoshan, Moshe

AU - Beyer, Kirsten

AU - Blumchen, Katharina

AU - Brough, Helen

AU - Caubet, Jean Christoph

AU - Chan, Edmond S.

AU - Chinthrajah, Sharon

AU - Davis, Carla M.

AU - Roches, Anne Des

AU - Du Toit, George

AU - Elizur, Arnon

AU - Galli, Stephen J.

AU - Håland, Geir

AU - Hoffmann-Sommergruber, Karin

AU - Kim, Harold

AU - Leung, Donald Y.M.

AU - Muraro, Antonella

AU - Nurmatov, Ulugbek B.

AU - Pajno, Giovanni B.

AU - Sindher, Sayantani

AU - Szepfalusi, Zsolt

AU - Torres, Maria Jose

AU - Upton, Julia

AU - Worm, Margitta

AU - Nadeau, Kari

N1 - Funding Information: Disclosures: Thomas Eiwegger received funding or has research contracts with DBV Technologies, ALK, Food Allergy and Anaphylaxis Program SickKids, Innovation Funds Denmark, and contributes to investigator-initiated OIT studies. Katherine Anagnostou has research contracts with Aimmune Therapeutics Inc and receives honoraria from ACAAI, and Colorado Allergy and Asthma Society (CAAS). Stefania Arasi has nothing to disclose. Philippe Bégin has received grants from Fonds de Recherche en Santé du Québec, Canadian Allergy, Asthma and Immunology Foundation, DBV Technologies, Sanofi Genzyme, Merck and Regeneron and personal fees from Aralez, Novartis and ALK outside the submitted work. Moshe Ben-Shoshan is a co-investigator for Aimmune and currently is involved in OIT studies. Kirsten Beyer reports outside the submitted work grants and personal fees from Aimmune, Danone, Infectopharm, personal fees from Bencard, Hycor, Mabylon AG, Mylan, Nestle, and grants from ALK, DBV Technologies, and Hipp. Katharina Blumchen has received personal fees and nonfinancial support from Novartis; personal fees from HAL Allergy, ThermoFisher, Bencard Allergie, Allergopharma, ALK, DBV, Nestle, Nutricia; grants and personal fees from Aimmune Therapeutics, and a grant from Hipp. Helen Brough serves on the UK Advisory Board for DBV Technologies and has received research support from ThermoScientific. Jean-Christoph Caubet has nothing to disclose. Edmond Chan has received research support from DBV Technologies, has been a member of advisory boards for Pfizer, Pediapharm, Leo Pharma, and Kaleo, is a member of the scientific advisory board for Food Allergy Canada, and was an expert panel and coordinating committee member of the National Institute of Allergy and Infectious Diseases (NIAID)-sponsored Guidelines for Peanut Allergy Prevention. Sharon Chinthrajah receives grant support from CoFAR NIAID, Aimmune, DBV Technologies, Astellas, AnaptysBio, Novartis, Regeneron, Stallergenes-Greer, and Boehringer Ingelheim, and is a scientific advisory board member for Alladapt Immunotherapeutics. Carla M. Davis is a co-investigator and contracts for Aimmune Therapeutics,Inc, DBV Technologies, Regeneron, Allakos, Inc, and the scientific advisory board for DBV technologies. Anne Des Roches has received grants from ALK and personal fees from Novartis and ALK outside the submitted work. George Du Toit is a scientific advisory board member of Aimmune, co-investigator on Aimmune-funded peanut Immunotherapy trials, UK Advisory Board for DBV Technologies, holds equity in DBV technologies, and is a lecturer at Allergy Symposia supported by Pharma companies, including Mylan and Aimmune. Arnon Elizur has nothing to disclose. Stephen J. Galli has received funding from NIH grants NIH/NIAID U19AI104209, NIH/NIAMS R01 AR067145, NIH/NIAID R01 AI125567, and NIH/NIAID R01 AI32494 and the United States-Israel Binational Foundation (Grant 2017182). Geir Haland has nothing to disclose. Karin Hoffmann-Sommergruber has received grants from Austrian Science Fund and Horizon 2020 (Cost action) and honoraria from Nutricia; and travel reimbursement from EAACI. Harold Kim served as speaker /or advisor for ALK, Aralez, Astrazeneca, CSL Behring, Shire, Novartis, Pediapharm, Stallergenes, Kaleo, Sanofi, Pfizer, and Mylan. Donald Y.M. Leung is Chairman of Aimmune Therapeutics, Inc DSMC; receives funding from NIH grants NIH/NIAMS R01 AR41256, NIH/NIAID U19 AI117673, NIH/NCRR UL1RR025780, NIH/NIAID UM1AI130780, and NIH/NIAID 1UM2AI130836, and consulted for Sanofi, Regeneron, Demira, and Novartis. Antonella Muraro has received a speaker's fee for DBV Technologies, Aimmune, serves as Chair of the EAACI Food Allergy and Anaphylaxis Guidelines. Ulugbek Nurmatov has nothing to disclose. Giovanni Battista Pajno has nothing to disclose. Sayantani Sindher conducted sponsored research for clinical trials from Aimmune, DBV Technologies, Sanofi, and Regeneron. Zsolt Szepfalusi has received honoraria from ThermoFisher, Milupa, Allergopharma, Shire, Bencard, Novartis, Meda, Vertex. Maria Jose Torres has been involved in collaboration with ALK-Abello. Julia Upton is a current or prior investigator for DBV Technologies, Aimmune, Regeneron, and investigator lead OIT studies (Food Allergy and Anaphylaxis Program SickKids), serves on the advisory board Kaleo, Food Allergy and Anaphylaxis Chair CSACI, and is a member of the scientific advisory board for Food Allergy Canada. Margitta Worm reports outside the submitted work grants and personal fees from Aimmune, Mylan, ALK, DBV Technologies, Allergopharma, Regenron, Sanofi, EliLilly, Stallergene, Bencard, HAL and Novartis. Kari Nadeau receives grant support from NIAID, Food Allergy Research & Education, End Allergies Together, Allergenis, Ukko; Personal Fees from Regeneron, AstraZeneca, ImmuneWorks, Cour; Sponsored research from Novartis, Sanofi, Astellas, Nestle; Sponsored research for clinical trials from Genentech, Aimmune Therapeutics, DBV Technologies, AnaptysBio, Stallergenes-Greer, Regeneron, and Adare Pharmaceuticals; Data and Safety Monitoring Board member at Novartis and NHLBI; Co-founded Before Brands, Alladapt Immunotherapeutics, and ForTra; Grant awardee for NIAID, NHLBI, NIEHS, and EPA; Director for Food Allergy Research & Education and WAO Center of Excellence. Funding Sources: None.

PY - 2019/11

Y1 - 2019/11

UR - http://www.scopus.com/inward/record.url?scp=85072215226&partnerID=8YFLogxK

U2 - 10.1016/j.anai.2019.09.001

DO - 10.1016/j.anai.2019.09.001

M3 - Article

C2 - 31513908

AN - SCOPUS:85072215226

SN - 1081-1206

VL - 123

SP - 430

EP - 432

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

IS - 5

ER -